The Pfizer laboratory has already started work on a new version of its COVID-19 vaccine aimed more specifically at the omicron variant, in case the current immunizer is not effective enough against this variation, The executive director of the American pharmaceutical company, Albert Bourla, assured this Monday.
“There are still many things that are unknown” about the new variant, detected in southern Africa and considered “worrisome” by the WHO, the executive said in an interview with the US network CNBC.
“We will know the essentials of what we need to know in a few weeks,” he added.
Trials will be conducted to evaluate the efficacy of the current vaccine, developed with BioNTech, against omicron. But if “it protects less and we see the need to create a new vaccine, we have started working since Friday. We have made our first DNA model, which is the first stage of the development of a new vaccine “he explained.
Pfizer has already created two new versions of its vaccine in less than a hundred days, against the delta and beta variants, which were ultimately not used. “In 95 days, we will have the new omicron vaccine”, Bourla said.
The Moderna laboratory, which also produces a vaccine against COVID-19, announced on Friday its intention to develop a specific booster dose for omicron.
The Pfizer director assured, however, that they continue to “trust” in the vaccine that is currently distributed, stating that the pharmacist used “a good dosage from the beginning.”
The anti-COVID-19 pill developed by Pfizer to treat the disease, which has been shown to be 89% effective against hospitalizations and deaths in clinical trials, was as “developed with the idea” that virus mutations would appear, Bourla said.
“I am confident in the ability (of the pill) to work with all mutations, including omicron,” he said.